Aerosol Drug Delivery Devices Market Size, Share & Trends Analysis Report By Type (Inhaler, Nebulizer), By Application (COPD, Asthma, Cystic Fibrosis), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Aerosol Drug Delivery Devices Market Growth & Trends

The global aerosol drug delivery devices market size is anticipated to reach USD 62.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a notable CAGR of 13.16% from 2025 to 2030. Major factors driving the market growth include the rising prevalence of respiratory diseases, increasing healthcare awareness, advancements in inhaler technology, and the growing demand for home-based treatments.

The market growth is driven by the increasing prevalence of respiratory diseases such as COPD, asthma, and cystic fibrosis, a growing focus on portable inhalation devices, and the need for quick, effective treatments. Other factors include government awareness campaigns, an aging population, technological advancements, higher device adoption, urbanization, pollution, and increased R&D.

Innovation in the market focuses on developing eco-friendly fuels, improving user-interface designs for better patient adherence, and using AI for personalized diagnostics and treatment. Research into biodegradable materials could provide sustainable alternatives for device construction. The market is competitive and fragmented, with rapid technological progress driving constant change. Companies proactively embrace trends, focusing on patient-centered, environmentally friendly solutions to seize growth opportunities.

Moreover, key players in the market, such as AptarGroup, Inc., Koninklijke Philips N.V., AstraZeneca, and Novartis AG, among others, are engaging in strategic initiatives such as partnerships, collaborations, new product launches, acquisitions, and expansions to strengthen their market position. For instance, in January 2024, Kindeva Drug Delivery announced the acquisition of Summit Biosciences, a company specializing in intranasal drug delivery.

“Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting. Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition not only fits Kindeva’s ambition to be a global leader in the drug-device combination products CDMO market but also expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally.”

- Kindeva CEO Milton Boyer.

Aerosol Drug Delivery Devices Market Report Highlights

• Based on type, the inhaler segment dominated the market with a revenue share of 89.59% in 2024 and is expected to witness the fastest growth at a CAGR over the forecast period owing to the advancement the development of technologically advanced products, and the growing adoption of digital solutions in the healthcare sector.
• Based on application, the COPD segment held the largest market share in 2024 and is anticipated to be the fastest-growing segment over the forecast period owing to the rising increasing prevalence worldwide.
• Based on the distribution channel, the institutional pharmacies segment held the largest market share in 2024, driven by the increasing need for bulk medication distribution, and the expanding patient population with respiratory conditions.
• North America dominated the aerosol drug delivery devices industry with a market share of 39.49% in 2024, owing to the advanced healthcare infrastructure, increasing geriatric population, and technological advancements.